Prelude Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Prelude Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,100	Closed	-$358K	–	1797
2020 Q4	$358K	Buy	+2,100	New	+$311K	0.01%	844
2020 Q3	–	Sell	-1,500	Closed	-$241K	–	2314
2020 Q2	$241K	Hold	1,500	–	–	0.01%	686
2020 Q1	$147K	Hold	1,500	–	–	0.01%	504
2019 Q4	$194K	Hold	1,500	–	–	0.01%	866
2019 Q3	$113K	Sell	1,500 -300	-17%	-$35.4K	0.01%	910
2019 Q2	$274K	Buy	1,800 +300	+20%	+$36.5K	0.01%	645
2019 Q1	$179K	Buy	+1,500	New	+$193K	0.01%	752
2018 Q3	–	Sell	-300	Closed	-$40K	–	2017
2018 Q2	$40K	Buy	+300	New	+$28.3K	﹤0.01%	1180
2016 Q4	–	Sell	-1,000	Closed	-$61K	–	1767
2016 Q3	$61K	Buy	+1,000	New	+$30.2K	0.01%	987
2016 Q1	–	Sell	-500	Closed	-$19K	–	1503
2015 Q4	$19K	Buy	+500	New	+$16.2K	﹤0.01%	1202
2014 Q2	–	Sell	-4,500	Closed	-$108K	–	2150
2014 Q1	$108K	Buy	+4,500	New	+$115K	0.01%	999
2013 Q4	–	Sell	-1,000	Closed	-$47K	–	1892
2013 Q3	$47K	Buy	+1,000	New	+$38.5K	0.01%	934

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prelude Capital Management's SRPT Position: Q3 2025 in Review

Prelude Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 13,135 shares — an estimated $225K sold.

Prelude Capital Management first reported a position in SRPT in Q2 2013 and held it in 32 quarters. The position peaked at $3.82M in Q3 2017. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Prelude Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 13,135 Sarepta Therapeutics shares in Q3 2025, an estimated $225K.
Prelude Capital Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 32 quarters.
Prelude Capital Management's Sarepta Therapeutics position peaked at $3.82M in Q3 2017.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.